Problem 4 - Brenner and Stevens’ Pharmacology

Question

Stimulation of lipoprotein lipase by a fenofibrate results in lowered serum levels of which substance? (A) triglycerides (B) HDL-cholesterol (C) LDL-cholesterol (D) apolipoprotein B (E) phospholipids

Step-by-Step Solution

Answer

(A) triglycerides

Step 1: Understanding Lipoprotein Lipase Activation

Lipoprotein lipase (LPL) is an enzyme that breaks down triglycerides into free fatty acids and glycerol. When stimulated, LPL increases the breakdown of triglycerides present in lipoproteins such as chylomicrons and VLDL (very-low-density lipoprotein) particles in the blood.

Step 2: Analyzing the Effect of Fenofibrate

Fenofibrate is a medication known to activate peroxisome proliferator-activated receptors (PPARs), which in turn stimulates lipoprotein lipase activity. This increased enzyme activity leads to the enhanced breakdown of triglycerides.

Step 3: Identifying the Serum Substance Affected

Given that lipoprotein lipase primarily targets triglycerides for breakdown, stimulated activity of this enzyme by fenofibrate would result in lowered serum triglyceride levels. Other substances, such as cholesterol or apolipoproteins, are not directly reduced by this mechanism.

Step 4: Selecting the Correct Option

Considering the breakdown of triglycerides due to increased lipoprotein lipase activity, option (A) triglycerides is selected as the substance with lowered serum levels as a result of fenofibrate stimulation.

Key Concepts

Lipoprotein Lipase

Lipoprotein lipase (LPL) plays a crucial role in fat metabolism. It acts as a biological scissors that breaks down fats. Specifically, it targets triglycerides found in the bloodstream within lipoproteins like chylomicrons and very-low-density lipoproteins (VLDL). These triglycerides are large molecules of dietary fat. They cannot directly enter the body's cells. Instead, lipoprotein lipase helps convert them into free fatty acids and glycerol, which can then be absorbed by cells.
The activity of LPL is essential for maintaining normal levels of triglycerides in the blood, and for providing cells with the energy they need. When LPL functions optimally, it helps prevent the build-up of triglycerides in the blood. This process is vital for energy balance and preventing conditions such as hyperlipidemia, which is an excess of fats in the bloodstream.
Deficiencies or malfunctions in lipoprotein lipase can lead to several cardiovascular diseases due to improper lipid metabolism. Proper functioning of LPL is essential not only for maintaining healthy triglyceride levels but also for overall metabolic health.

Fenofibrate Mechanism

Fenofibrate is a medication primarily used in the management of dyslipidemia, a condition characterized by abnormal lipid levels in the blood. It works by activating a specific class of nuclear receptor proteins known as peroxisome proliferator-activated receptors (PPARs). The activation of PPARs, in particular PPAR-alpha, leads to a cascade of metabolic activities. One of the most significant outcomes of this activation is the stimulation of lipoprotein lipase activity.
When fenofibrate boosts LPL, it enhances the breakdown of triglycerides into free fatty acids and glycerol. This process effectively lowers triglyceride levels in the bloodstream. Furthermore, fenofibrate has been shown to increase the size of low-density lipoprotein (LDL) particles, which may also reduce cardiovascular risks.

• Increases fatty acid oxidation
• Lowers triglyceride levels
• Reduces small, dense LDL particles

Fenofibrate has the additional beneficial effects of potentially reducing inflammatory processes and improving insulin sensitivity. Such multifunctional benefits make fenofibrate a valuable agent in treating lipid disorders.

Triglycerides Reduction

Triglycerides serve as a major form of energy storage in the body, stored in fat tissues. However, when levels become elevated in the bloodstream, it increases the risk of cardiovascular diseases. Managing these levels is crucial for maintaining cardiovascular health.
Lipoprotein lipase is the key enzyme responsible for reducing triglyceride levels. Once activated, it breaks down triglycerides into absorbable components. This enzymatic process is significantly enhanced by medications like fenofibrate.

• Excess triglycerides are linked to heart disease
• LPL activation is critical for lowering high triglyceride levels

Fenofibrate aids in this reduction by activating lipoprotein lipase. As LPL activity increases, triglyceride molecules are more effectively broken down and removed from circulation. Thus, increased LPL activity through fenofibrate not only directly lowers triglyceride levels but also contributes to overall heart health by reducing the associated risks.